Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D.
Frida WelanderHenrik RenlundEmöke DiményHenrik HolmbergAnders SjälanderPublished in: Clinical kidney journal (2023)
DOAC treatment, compared with warfarin, is associated with almost 30% lower risk of bleeding in patients with NVAF and CKD G3-G5D. The stroke risk is comparable between the treatments. This is the first study comparing DOAC and well-managed warfarin (TTR 67%) in advanced CKD. Ongoing and planned randomized controlled trials need to confirm the possible benefit of DOAC.
Keyphrases
- direct oral anticoagulants
- atrial fibrillation
- chronic kidney disease
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- heart failure
- randomized controlled trial
- venous thromboembolism
- coronary artery disease
- clinical trial
- aortic valve
- brain injury
- subarachnoid hemorrhage
- cerebral ischemia
- replacement therapy